🚀Clinical Research

Twenty years of iPSCs: safety and trust put to the test as therapies approach commercialization

Nature·August 18, 2026AI Curation
Twenty years of iPSCs: safety and trust put to the test as therapies approach commercialization
✨AI Summary (Beta)Beta

Background

Induced pluripotent stem cell (iPSC) technology has reached its 20th anniversary. A Nature editorial published on August 18, 2026, identified safety testing and maintaining public trust as key challenges as iPSC therapies move toward clinical use. In 2006, Kyoto University researchers Shinya Yamanaka and Kazutoshi Takahashi showed that activating four genes in adult mouse cells could erase their identity and return them to a state resembling embryonic stem cells. If these cells could then be differentiated into needed tissues, they could offer a source of cells for repairing damaged organs.

The discovery was later replicated in human cells. Patient-derived cells are also used to build disease models, investigate molecular mechanisms of disease, and explore drug candidates. Researchers are developing organoids, three-dimensional cell clusters that model the structure and function of organs. Pharmaceutical companies use iPSCs in drug discovery for conditions including amyotrophic lateral sclerosis (ALS).

Key findings

iPSC technology is moving beyond laboratory research into clinical development aimed at treating patients. According to the editorial, two iPSC-derived therapies, for Parkinson’s disease and heart failure, received conditional approval in Japan in 2026. Researchers are still collecting additional data after assessing safety in small early-stage clinical studies. Conditional approval alone does not establish safety and efficacy. Results from several clinical trials targeting conditions such as macular degeneration and diabetes are also expected to be reported over the five years following the editorial’s publication.

It took years of development to reliably obtain the cells needed for treatment. When a team led by Deepak Srivastava at the Gladstone Institutes in the United States first made heart cells from iPSCs, the proportion that differentiated into heart cells was only about 1%. After years of research, the team raised this proportion to more than 90% and observed the heart cells beating spontaneously in unison in culture. These figures describe that laboratory’s experience with cardiac differentiation; they do not refer to the efficiency of reprogramming adult cells into iPSCs.

The possibility that undifferentiated cells could form tumors in a patient remains a major safety concern. Developers must check whether treatment cells have differentiated to perform the intended function and whether any undifferentiated cells capable of causing tumors remain. The editorial explains that these checks have lengthened therapy development.

Significance and outlook

iPSC research is at a turning point, requiring consideration of both responsible therapy development and access. The editorial warned that rushing development without appropriate guidance could increase the risk of harm to patients, and that harm in clinical trials could set back the entire field. Its message is that validation must continue even amid competition to bring therapies to market first.

Reducing high manufacturing costs so more patients can receive treatment remains another challenge. In many cases, making a tailored therapy from each patient’s own cells is time-consuming and costly, limiting its practicality. Researchers are therefore developing a broadly usable alternative in which iPSCs from one donor could be used to treat multiple people. Together with manufacturing process improvements, this approach could lower costs and improve access, but it does not mean that a treatment system available to everyone is already in place. Yamanaka likened translational research to a marathon and emphasized that patients’ interests should guide development.

Source: Nature editorial, August 18, 2026

Nature, Published online: 18 August 2026; doi:10.1038/d41586-026-02524-2It is 20 years since induced pluripotent stem cells shook biomedicine. Public trust must be retained now that clinical trials are well under way.

💬Why it matters:

Developing iPSC therapies requires validating not only the cells’ ability to differentiate to perform the desired function, but also whether undifferentiated cells remain and whether the therapy is safe for patients. Data collection is ongoing after initial safety studies in Japan’s two conditional-approval cases. On the supply side, one concrete development scenario is to make therapies for multiple patients from a single donor’s iPSCs. Reducing the burden of producing cells separately for each patient and improving manufacturing processes could lower costs and improve access. However, the provided editorial contains no data on actual manufacturing costs, supply times, or patient-specific suitability, so readiness for immediate administration or reduced immune rejection cannot be assumed.

💬 Comments

0 comments
Please log in to comment
Loading...

BioPlayground

Reading, linking, and lawful quotation stay open; high-speed bulk collection and unauthorized redistribution do not.

Unless stated otherwise, content rights belong to BioPlayground or the relevant rights holder.